Aster DM Healthcare Q3 FY26 Revenue Up 13% to ₹1,186 Cr; Combined Proforma Revenue Up 15% to ₹2,366 Cr
Aster DM Healthcare reported Q3 FY26 standalone revenue of ₹1,186 crore, up 13% YoY, with operating EBITDA up 17% to ₹237 crore. The combined proforma entity (Aster + QCIL) saw Q3 FY26 revenue rise 15% to ₹2,366 crore and operating EBITDA increase 22% to ₹503 crore. A shareholders' meeting for the merger is scheduled between Feb 27 and Mar 13, 2026, with completion expected by Q1 FY27.
The announcement includes strong financial performance metrics and significant progress on a major merger, which are material events for the company and its stakeholders.
The company has reported positive financial results with significant year-on-year growth in revenue and operating EBITDA for both standalone and combined proforma entities. The progress on the merger also indicates positive forward momentum.
Aster DM Healthcare has announced its financial results for the quarter and nine months ended December 31, 2025. For the third quarter of fiscal year 2026 (Q3 FY26), the company reported a standalone revenue growth of 13% year-on-year, reaching ₹1,186 crore. The operating EBITDA, excluding the Kasaragod facility, saw a 17% year-on-year increase to ₹237 crore, with operating EBITDA margins expanding to 20.2% from 19.3% in Q3 FY25. Normalised PAT (excluding Kasaragod) grew by 22% year-on-year to ₹98 crore.
On a combined proforma basis, including Quality Care India Ltd (QCIL), the revenues for Q3 FY26 grew by 15% year-on-year to ₹2,366 crore, and operating EBITDA increased by 22% year-on-year to ₹503 crore, with an operating EBITDA margin of 21%. The combined entity, which includes over 10,620 beds across 28 cities, is working towards becoming one of the top three hospital chains in India.
The merger between Aster and QCIL is progressing, with a shareholders' meeting scheduled to be convened between February 27, 2026, and March 13, 2026, as directed by the NCLT. The transaction is expected to be completed by Q1 FY27. QCIL also reported strong Q3 FY26 performance with a 17% year-on-year revenue increase to ₹1,181 crore and a 32% rise in operating EBITDA to ₹279 crore, achieving an operating EBITDA margin of 23.7%.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.